This Biotech Found Significant Success Following Key Announcement

By: Dylan Sikes – AllPennyStocks.com News

Wednesday, December 4, 2024

A New York-based biotech company is stealing the mid-week show after it announced the broadening of its Phase 2 clinical trial for non-active secondary progressive multiple sclerosis to addition US medical institutions, according to a press release this morning.

Traders were quick to buy up shares of Tiziana Life Sciences Ltd (Nasdaq:TLSA), pushing the price of this small cap to close the session at $1.02/share (+12.09%). This stock has been trading in a range for the last few months, but if it gets a boost like today’s move more often, this thing could be off to the races!

Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for autoimmune and inflammatory diseases, degenerative diseases, and cancer-related to the liver. Its clinical pipeline includes drug assets for Crohn's Disease, COVID19, Secondary Progressive Multiple Sclerosis, and Hepatocellular Carcinoma. Its development pipeline includes Foralumab, Milciclib, Anti-IL6R, and Others. The company has a single reporting segment, which is the research and development of biotechnological & pharmaceutical products.

Copyright © 2024 AllPennyStocks.com. All rights reserved. Republication or redistribution of AllPennyStocks.com's content is expressly prohibited without the prior written consent of AllPennyStocks.com. AllPennyStocks.com shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.